collection
MENU ▼
Read by QxMD icon Read
search

MMCBreast Collection

shared collection
167 papers 100 to 500 followers
https://www.readbyqxmd.com/read/27903276/accurate-prediction-of-response-to-endocrine-therapy-in-breast-cancer-patients-current-and-future-biomarkers
#1
REVIEW
Cigdem Selli, J Michael Dixon, Andrew H Sims
Approximately 70% of patients have breast cancers that are oestrogen receptor alpha positive (ER+) and are therefore candidates for endocrine treatment. Many of these patients relapse in the years during or following completion of adjuvant endocrine therapy. Thus, many ER+ cancers have primary resistance or develop resistance to endocrine therapy during treatment. Recent improvements in our understanding of how tumours evolve during treatment with endocrine agents have identified both changes in gene expression and mutational profiles, in the primary cancer as well as in circulating tumour cells...
December 1, 2016: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/27906762/complications-in-postmastectomy-breast-reconstruction-one-year-outcomes-of-the-mastectomy-reconstruction-outcomes-consortium-mroc-study
#2
Edwin G Wilkins, Jennifer B Hamill, Hyungjin M Kim, John Y Kim, Richard J Greco, Ji Qi, Andrea L Pusic
OBJECTIVE: In postmastectomy reconstruction, procedure choice is heavily influenced by the relative risks of the various options. This study sought to evaluate complications in a large, multicenter patient population. SUMMARY OF BACKGROUND DATA: Previous studies have reported widely varying complication rates, but have been limited by their single center designs and inadequate controlling for confounders in their analyses. METHODS: Eleven sites enrolled women undergoing first time, immediate, or delayed reconstruction following mastectomy for cancer treatment or prophylaxis...
November 30, 2016: Annals of Surgery
https://www.readbyqxmd.com/read/27898991/nipple-and-areola-sparing-mastectomy-for-the-treatment-of-breast-cancer
#3
REVIEW
Bruna S Mota, Rachel Riera, Marcos Desidério Ricci, Jessica Barrett, Tiago B de Castria, Álvaro N Atallah, Jose Luiz B Bevilacqua
BACKGROUND: The efficacy and safety of nipple-sparing mastectomy and areola-sparing mastectomy for the treatment of breast cancer are still questionable. It is estimated that the local recurrence rates following nipple-sparing mastectomy are very similar to breast-conserving surgery followed by radiotherapy. OBJECTIVES: To assess the efficacy and safety of nipple-sparing mastectomy and areola-sparing mastectomy for the treatment of ductal carcinoma in situ and invasive breast cancer in women...
November 29, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27775837/chemotherapy-decisions-and-patient-experience-with-the-recurrence-score-assay-for-early-stage-breast-cancer
#4
Christopher R Friese, Yun Li, Irina Bondarenko, Timothy P Hofer, Kevin C Ward, Ann S Hamilton, Dennis Deapen, Allison W Kurian, Steven J Katz
BACKGROUND: The 21-gene recurrence score (RS) assay stratifies early-stage, estrogen receptor-positive breast cancer by recurrence risk. Few studies have examined the ways in which physicians use the RS to recommend adjuvant systemic chemotherapy or patients' experiences with testing and decision making. METHODS: This study surveyed 3880 women treated for breast cancer in 2013-2014; they were identified from the Los Angeles County and Georgia Surveillance, Epidemiology, and End Results registries (response rate, 71%)...
October 24, 2016: Cancer
https://www.readbyqxmd.com/read/27865536/breast-cancer
#5
REVIEW
Nadia Harbeck, Michael Gnant
Breast cancer is one of the three most common cancers worldwide. Early breast cancer is considered potentially curable. Therapy has progressed substantially over the past years with a reduction in therapy intensity, both for locoregional and systemic therapy; avoiding overtreatment but also undertreatment has become a major focus. Therapy concepts follow a curative intent and need to be decided in a multidisciplinary setting, taking molecular subtype and locoregional tumour load into account. Primary conventional surgery is not the optimal choice for all patients any more...
November 16, 2016: Lancet
https://www.readbyqxmd.com/read/27866091/a-sensitivity-and-specificity-comparison-of-fine-needle-aspiration-cytology-and-core-needle-biopsy-in-evaluation-of-suspicious-breast-lesions-a-systematic-review-and-meta-analysis
#6
REVIEW
Mei Wang, Xiaoning He, Yaping Chang, Guangwen Sun, Lehana Thabane
PURPOSE: Breast cancer detections for women with suspicious lesions mainly depend on two non-operative pathological tests-fine needle aspiration cytology (FNAC) and core needle biopsy (CNB). The aim of this systematic review was to compare the sensitivity and specificity of CNB and FNAC in this setting. METHODS: The data sources included MEDLINE, EMBASE, PubMed, and the Cochrane Central Register of Controlled Trials (CENTRAL) till February 2016. We included prospective series of studies which directly compared the accuracy of FNAC and CNB...
November 17, 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27855963/immunotherapy-in-breast-cancer-an-overview-of-modern-checkpoint-blockade-strategies-and-vaccines
#7
REVIEW
Katherine Sanchez, David Page, Heather L McArthur
No abstract text is available yet for this article.
September 26, 2016: Current Problems in Cancer
https://www.readbyqxmd.com/read/27725895/breast-cancer-molecular-subtypes-from-tnbc-to-qnbc
#8
Jane Date C Hon, Baljit Singh, Aysegul Sahin, Gang Du, Jinhua Wang, Vincent Y Wang, Fang-Ming Deng, David Y Zhang, Marie E Monaco, Peng Lee
Treatment protocols for breast cancer depend predominantly on receptor status with respect to estrogen (estrogen receptor alpha), progesterone (progesterone receptor) and human epidermal growth factor [human epidermal growth factor receptor 2 (HER2)]. The presence of one or more of these receptors suggests that a treatment targeting these pathways might be effective, while the absence of, or in the case of HER2, lack of overexpression of, all of these receptors, termed triple negative breast cancer (TNBC), indicates a need for the more toxic chemotherapy...
2016: American Journal of Cancer Research
https://www.readbyqxmd.com/read/27815046/the-impact-of-the-biomolecular-era-on-breast-cancer-surgery
#9
REVIEW
T P McVeigh, M R Boland, A J Lowery
Surgery has always played a central role in the management of breast cancer, with local control via complete tumour resection long established as the cornerstone of effective breast cancer therapy. While extensive surgical resection in the form of the Halstead radical mastectomy dominated treatment up until at least the 1970s, the advent of adjuvant loco-regional and systemic therapies has resulted in a decrease in the magnitude of surgical intervention in recent decades. The Biomolecular or "-omics" era initiated with the discovery of the DNA double helix in 1953 and intensified by the completion of the human genome project in 2003 has seen an unprecedented expansion in our understanding of the molecular and genetic heterogeneity of cancer...
November 1, 2016: Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
https://www.readbyqxmd.com/read/27836010/inheritance-of-deleterious-mutations-at-both-brca1-and-brca2-in-an-international-sample-of-32-295-women
#10
Timothy R Rebbeck, Tara M Friebel, Nandita Mitra, Fei Wan, Stephanie Chen, Irene L Andrulis, Paraskevi Apostolou, Norbert Arnold, Banu K Arun, Daniel Barrowdale, Javier Benitez, Raanan Berger, Pascaline Berthet, Ake Borg, Saundra S Buys, Trinidad Caldes, Jonathan Carter, Jocelyne Chiquette, Kathleen B M Claes, Fergus J Couch, Cezary Cybulski, Mary B Daly, Miguel de la Hoya, Orland Diez, Susan M Domchek, Katherine L Nathanson, Katarzyna Durda, Steve Ellis, D Gareth Evans, Lenka Foretova, Eitan Friedman, Debra Frost, Patricia A Ganz, Judy Garber, Gord Glendon, Andrew K Godwin, Mark H Greene, Jacek Gronwald, Eric Hahnen, Emily Hallberg, Ute Hamann, Thomas V O Hansen, Evgeny N Imyanitov, Claudine Isaacs, Anna Jakubowska, Ramunas Janavicius, Katarzyna Jaworska-Bieniek, Esther M John, Beth Y Karlan, Bella Kaufman, KConFab Investigators, Ava Kwong, Yael Laitman, Christine Lasset, Conxi Lazaro, Jenny Lester, Niklas Loman, Jan Lubinski, Siranoush Manoukian, Gillian Mitchell, Marco Montagna, Susan L Neuhausen, Heli Nevanlinna, Dieter Niederacher, Robert L Nussbaum, Kenneth Offit, Edith Olah, Olufunmilayo I Olopade, Sue Kyung Park, Marion Piedmonte, Paolo Radice, Christine Rappaport-Fuerhauser, Matti A Rookus, Caroline Seynaeve, Jacques Simard, Christian F Singer, Penny Soucy, Melissa Southey, Dominique Stoppa-Lyonnet, Grzegorz Sukiennicki, Csilla I Szabo, Mariella Tancredi, Manuel R Teixeira, Soo-Hwang Teo, Mary Beth Terry, Mads Thomassen, Laima Tihomirova, Marc Tischkowitz, Amanda Ewart Toland, Aleksandra Toloczko-Grabarek, Nadine Tung, Elizabeth J van Rensburg, Danylo Villano, Shan Wang-Gohrke, Barbara Wappenschmidt, Jeffrey N Weitzel, Jamal Zidan, Kristin K Zorn, Lesley McGuffog, Douglas Easton, Georgia Chenevix-Trench, Antonis C Antoniou, Susan J Ramus
BACKGROUND: Most BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the consequences of transheterozygosity are poorly understood. METHODS: From 32,295 female BRCA1/2 mutation carriers, we identified 93 TH (0.3 %). "Cases" were defined as TH, and "controls" were single mutations at BRCA1 (SH1) or BRCA2 (SH2). Matched SH1 "controls" carried a BRCA1 mutation found in the TH "case"...
November 11, 2016: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/27848050/sentinel-lymph-node-based-management-or-routine-axillary-clearance-five-year-outcomes-of-the-racs-sentinel-node-biopsy-versus-axillary-clearance-snac-1-trial-assessment-and-incidence-of-true-lymphedema
#11
Neil Wetzig, Peter Grantley Gill, David Espinoza, Rebecca Mister, Martin R Stockler, Val J Gebski, Owen A Ung, Ian Campbell, John Simes
PURPOSE: To determine whether the benefits of sentinel-node-based management (SNBM) over routine axillary clearance (RAC) persisted to 5 years. METHODS: A total of 1088 women with breast cancer less than 3 cm in diameter and clinically negative axillary nodes were randomized to SNBM with axillary clearance if the sentinel node was positive or RAC preceded by sentinel-node biopsy. The outcomes were: (1) objectively measured change in the volume of the operated and contralateral nonoperated arms; (2) the proportion with an increase in arm volume <15%; and (3) subjectively assessed arm morbidity for the domains swelling, symptoms, dysfunction, and disability...
November 15, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27839746/metastatic-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-management-challenges-and-future-directions
#12
REVIEW
Mohsin Soleja, Mothaffar F Rimawi
No abstract text is available yet for this article.
September 19, 2016: Current Problems in Cancer
https://www.readbyqxmd.com/read/27823654/aromatase-inhibitors-in-premenopause-great-expectations-fulfilled
#13
REVIEW
Rosalba Torrisi, Selene Rota, Agnese Losurdo, Monica Zuradelli, Giovanna Masci, Armando Santoro
Tamoxifen and GnRH analogues (GnRHa) represent the mainstay of endocrine manipulations in premenopausal women. The estrogen blockade obtained by aromatase inhibitors (AIs) plus GnRHa suppresses circulating estrogens more deeply than tamoxifen plus GnRHa. Retrospective and prospective evidence confirm a substantial activity for AIs and GnRHa in locally advanced and metastatic breast cancer. In early breast cancer inconsistent evidence emerged from 2 large randomized studies with anastrozole performing as tamoxifen in terms of DFS, but significantly worse as of OS while exemestane outperformed tamoxifen as of DFS particularly in very young and high-risk women...
November 2016: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/27810699/improved-survival-in-metastatic-breast-cancer-1985-2016
#14
Marie Sundquist, Lars Brudin, Göran Tejler
PURPOSE: In the last 25 years new treatment options in breast cancer have evolved. We wanted to determine whether the survival of; patients with metastatic breast cancer have improved during this period. METHODS: Patients consecutively diagnosed with disseminated breast cancer 1985-2014 in the County of Kalmar, Sweden, were identified and followed to 2016. Survival was calculated for each successive 5 year interval. Separate analyses were performed for pts with ER and/or PR and HER2 positive tumours resp...
October 28, 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27826664/anti-her2-cd4-t-helper-type-1-immune-response-is-superior-to-breast-mri-for-assessing-response-to-neoadjuvant-therapy-in-patients-with-her2-positive-breast-cancer
#15
Lucy M De La Cruz, Elizabeth S McDonald, R Mick, Jashodeep Datta, Nadia F Nocera, Shuwen Xu, Carla S Fisher, Brian J Czerniecki
BACKGROUND: In human epidermal growth factor 2-positive breast cancer (HER2(+)BC), neoadjuvant chemotherapy and anti-HER2-targeted therapy (nCT) achieves a complete pathologic response (pCR) in 40-67% of patients. Posttreatment magnetic resonance imaging (pMRI) is considered the gold standard, with high specificity but lower sensitivity for assessing response. The authors previously determined that anti-HER2Th1 immune response is associated with pathologic response after nCT in HER2(+)BC patients...
November 8, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27822630/outcomes-of-sentinel-lymph-node-positive-breast-cancer-patients-treated-with-mastectomy-without-axillary-therapy
#16
Elizabeth FitzSullivan, Roland L Bassett, Henry M Kuerer, Elizabeth A Mittendorf, Min Yi, Kelly K Hunt, Gildy V Babiera, Abigail S Caudle, Dalliah M Black, Isabelle Bedrosian, Chantal Reyna, Mediget Teshome, Funda Meric-Bernstam, Rosa Hwang
PURPOSE: Early-stage breast cancer patients with minimal axillary disease identified by sentinel lymph node dissection (SLND) have low regional recurrence rates when treated with breast-conserving surgery and radiation therapy (XRT) and many avoid a completion axillary lymph node dissection (CLND). As the incidence of total mastectomy (TM) has increased, it has become important to characterize which TM patients with a positive SLN may not benefit from further axillary treatment. METHODS: An institutional database was utilized to identify patients treated with a TM for invasive breast cancer and who had a positive SLN from 1994 to 2010...
October 3, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27598038/meta-analysis-of-aberrant-lymphatic-drainage-in-recurrent-breast-cancer
#17
REVIEW
M Ahmed, R Baker, I T Rubio
BACKGROUND: Sentinel node biopsy (SNB) in recurrent breast cancer offers targeted axillary staging compared with axillary lymph node dissection (ALND) or no treatment. The evidence for lymphatic mapping in recurrent breast cancer is reviewed, focusing on aberrant drainage and its implications for patient management. METHODS: A meta-analysis of studies evaluating lymphatic mapping in recurrent breast cancer was performed. Outcomes included sentinel node identification, aberrant lymphatic pathways and metastatic node rates in aberrant drainage and ipsilateral axilla...
November 2016: British Journal of Surgery
https://www.readbyqxmd.com/read/27807728/chemotherapy-significantly-improves-survival-for-patients-with-t1c-t2n0m0-medullary-breast-cancer-3739-cases-from-the-national-cancer-data-base
#18
Alina M Mateo, Todd A Pezzi, Mark Sundermeyer, Cynthia A Kelley, V Suzanne Klimberg, Christopher M Pezzi
BACKGROUND: Medullary breast cancer (MBC) is a rare tumor associated with a better prognosis compared with other breast cancers. The role of adjuvant chemotherapy has not been extensively studied. METHODS: Female patients with invasive MBC reported to the National Cancer Data Base from 2004 to 2012 were analyzed. Overall survival (OS) and treatment were studied using the Kaplan-Meier method and the Cox proportional hazard model. Patients who had node-negative (N0), non-metastatic (M0) tumors 10 to 50 mm in size (T1cN0M0 and T2N0M0) treated with and without chemotherapy were analyzed using propensity score matching...
November 2, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27161491/the-somatic-mutation-profiles-of-2-433-breast-cancers-refines-their-genomic-and-transcriptomic-landscapes
#19
Bernard Pereira, Suet-Feung Chin, Oscar M Rueda, Hans-Kristian Moen Vollan, Elena Provenzano, Helen A Bardwell, Michelle Pugh, Linda Jones, Roslin Russell, Stephen-John Sammut, Dana W Y Tsui, Bin Liu, Sarah-Jane Dawson, Jean Abraham, Helen Northen, John F Peden, Abhik Mukherjee, Gulisa Turashvili, Andrew R Green, Steve McKinney, Arusha Oloumi, Sohrab Shah, Nitzan Rosenfeld, Leigh Murphy, David R Bentley, Ian O Ellis, Arnie Purushotham, Sarah E Pinder, Anne-Lise Børresen-Dale, Helena M Earl, Paul D Pharoah, Mark T Ross, Samuel Aparicio, Carlos Caldas
The genomic landscape of breast cancer is complex, and inter- and intra-tumour heterogeneity are important challenges in treating the disease. In this study, we sequence 173 genes in 2,433 primary breast tumours that have copy number aberration (CNA), gene expression and long-term clinical follow-up data. We identify 40 mutation-driver (Mut-driver) genes, and determine associations between mutations, driver CNA profiles, clinical-pathological parameters and survival. We assess the clonal states of Mut-driver mutations, and estimate levels of intra-tumour heterogeneity using mutant-allele fractions...
May 10, 2016: Nature Communications
https://www.readbyqxmd.com/read/27797159/disparities-in-the-local-management-of-breast-cancer-in-the-us-according-to-health-insurance-status
#20
Thomas M Churilla, Brian Egleston, Richard Bleicher, Yanqun Dong, Joshua Meyer, Penny Anderson
Although standard practice guidelines for breast cancer are clear, the interplay between insurance and practice patterns for the US is poorly defined. This study was performed to test for associations between patient insurance status and presentation of breast cancer as well as local therapy patterns in the US, via a large national dataset. We queried the NCI Surveillance, Epidemiology, and End Results data base for breast cancer cases diagnosed from 2007 to 2011 in women aged 18-64 with nonmetastatic ductal/lobular cancers, treated surgically...
October 31, 2016: Breast Journal
label_collection
label_collection
6331
1
2
2016-11-02 15:26:57
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"